Home  /  News

This is the first pharmaceutical Rapid Collaborative Review (PTRCR15) for – Remdesivir for the treatment of COVID-19. PICO and Evidence gaps.In June, 2020, the European Commission granted marketing authorisation for Veklury® (remdesivir) for the treatment of Covid-19. This Rapid Collaborative Review aims

EUnetHTA deems patient involvement very important in the production of Joint Assessment reports. We recognise that patients and those who support them have unique knowledge about what it is like to live with a specific disease or medical condition. We

​​This is the pharmaceutical Joint Assessment PTJA14 – Pretomanid in combination with bedaquiline and linezolid in adults for the treatment of pulmonary extensively drug-resistant (XDR), or treatment-intolerant or nonresponsive multidrug-resistant (MDR) tuberculosis (TB).In August, 2020, the European Commission granted marketing

EUnetHTA is pleased to announce the publication of the final project plan of its Rapid Collaborative Review on the diagnostic accuracy of molecular methods that detect the presence of SARS-CoV-2 virus in people with suspected COVID-19.This is the second one of

The Other Technologies Collaborative Assessment OTCA23 final assessment report "Biodegradable rectum spacers to reduce toxicity for prostate cancer'', together with related documentation, is now available for access.The assessed technology is biodegradable rectum spacers added to conventional radiotherapy to (temporarily) position

The final project plan of the assessment on “Comparative effectiveness of surgical techniques and devices for the treatment of benign prostatic hyperplasia (BPH)” is now available. Comments from external experts and answers of the Authoring Team are also accessible. This

This is the pharmaceutical Joint Assessment PTJA12 - on glasdegib for the treatment of acute myeloid leukaemia (AML). In June 2020, the European Commission granted marketing authorisation for Daurismo® (glasdegib), in combination with low-dose cytarabine, for the treatment of newly

The final project plan of the relative effectiveness assessment of 'crizanlizumab indicated for the prevention of recurrent vast-occlusive crises in sickle cell disease patients aged 16 years and over' is now available for access. The final assessment report will be